Company: LENZ
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001628280-25-016822
Chunk: 50

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: S-3
Chunk 50
---
 | 7.41 |     |   |       |
| Increase in net tangible book value per share attributable to new investors purchasing shares of common stock in this offering |     | $ | 2.84 |     |   |       |
| As adjusted net tangible book value per share as of December 31, 2024, after giving effect to this offering                    |     |   |      |     | $ | 10.25 |
| Dilution per share to investors purchasing our common stock in this offering                                                   |     |   |      |     | $ | 12.75 |

The dilution per share in the table above is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our common stock are sold pursuant to this prospectus supplement. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $23.00 per share shown in the table above, assuming all of our common stock in the aggregate amount of $150.0 million is sold at that price, would cause our as adjusted net tangible book value per share after the offering to be $10.34 per share and would increase the dilution in net tangible book value per share to new investors to $13.66 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $23.00 per share shown in the table above, assuming all of our common stock in the aggregate amount of $150.0 million is sold at that price, would cause our as adjusted net tangible book value per share after the offering to be $10.16 per share and would decrease the dilution in net tangible book value per share to new investors to $11.84 per share, after deducting commissions and estimated aggregate offering expenses payable by us.

To the extent that outstanding options are exercised, investors purchasing our common stock in this offering will experience further dilution. In addition, to the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

The above table and discussion of shares of our common stock that will be outstanding after this offering is based